Program Information
3 Year Clinical Experience with the IBA Proton Eyeline
E Kryck*, M Mamalui-Hunter , Z Li , r slopsema , University of Florida/Radiation Oncology, Jacksonville, FL
Presentations
SU-E-T-3 (Sunday, July 12, 2015) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose: Over the past 3 years, more than 50 patients with ocular disease have been treated with a prototype commercial eyeline developed by Ion Beam Applications (IBA). It is particularly crucial for the dosimetry of the machine to be accurate, precise, and reproducible because of the small treatment volumes and several surrounding critical structures. A quality assurance (QA) program has been developed in order to regularly check and record the machine’s dosimetry over time. In this study we have summarized and evaluated three years of patient and system QA data for the eyeline prototype.
Methods: In order to accurately deliver the prescribed dose to the patient’s treatment site, an output model was created based on several machine parameters. This output model, along with the requested system parameters, are regularly checked and recorded by a QA program. 10 standard proton fields have been created which have regular QA performed monthly with a water tank and parallel-plate chamber, and recorded in a database. QA has additionally been performed for each patient-specific treatment field. This is to verify and evaluate the patient output model as well as the system parameters for range & modulation combinations different than the standard QA fields.
Results: 140 beam measurements have been analyzed for range, modulation, and output. The range is typically within tolerance, although there are about 6 cases where the system did not perform as expected. The modulation appears to be very stable, always being within tolerance. Output for the standard QA fields are typically within 2.5% from the baseline value. The patient output measurements agree within 2.5% from the model.
Conclusion: Overall the eyeline performs well within the tolerances set, and the patient output measurements agree within 2% of the model.
Contact Email: